

Matthias G Edinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8564569/publications.pdf>

Version: 2024-02-01

101
papers

12,756
citations

81900

39
h-index

46799

89
g-index

102
all docs

102
docs citations

102
times ranked

20062
citing authors

#	ARTICLE	IF	CITATIONS
1	A promoter-level mammalian expression atlas. <i>Nature</i> , 2014, 507, 462-470.	27.8	1,838
2	Inhibitory effect of tumor cell-derived lactic acid on human T cells. <i>Blood</i> , 2007, 109, 3812-3819.	1.4	1,361
3	CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. <i>Nature Medicine</i> , 2003, 9, 1144-1150.	30.7	1,174
4	Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation. <i>Journal of Experimental Medicine</i> , 2002, 196, 389-399.	8.5	1,012
5	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	2.9	766
6	DNA demethylation in the human <i>FOXP3</i> locus discriminates regulatory T cells from activated <i>FOXP3</i> ⁺ conventional T cells. <i>European Journal of Immunology</i> , 2007, 37, 2378-2389.	2.9	620
7	Large-scale in vitro expansion of polyclonal human CD4+CD25 ^{high} regulatory T cells. <i>Blood</i> , 2004, 104, 895-903.	1.4	461
8	Metagenomic Analysis of the Stool Microbiome in Patients Receiving Allogeneic Stem Cell Transplantation: Loss of Diversity Is Associated with Use of Systemic Antibiotics and More Pronounced in Gastrointestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 640-645.	2.0	444
9	Only the CD62L ⁺ subpopulation of CD4+CD25 ⁺ regulatory T cells protects from lethal acute GVHD. <i>Blood</i> , 2005, 105, 2220-2226.	1.4	379
10	Only the CD45RA ⁺ subpopulation of CD4+CD25 ^{high} T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. <i>Blood</i> , 2006, 108, 4260-4267.	1.4	372
11	Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. <i>Blood</i> , 2003, 101, 640-648.	1.4	302
12	Loss of <i>FOXP3</i> expression in natural human CD4 ⁺ CD25 ⁺ regulatory T cells upon repetitive <i>in vitro</i> stimulation. <i>European Journal of Immunology</i> , 2009, 39, 1088-1097.	2.9	298
13	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. <i>Lancet</i> , 2020, 395, 1627-1639.	13.7	266
14	Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. <i>Leukemia</i> , 2017, 31, 2398-2406.	7.2	232
15	Noninvasive Assessment of Tumor Cell Proliferation in Animal Models. <i>Neoplasia</i> , 1999, 1, 303-310.	5.3	224
16	Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. <i>Genome Research</i> , 2009, 19, 1165-1174.	5.5	206
17	FANTOM5 CAGE profiles of human and mouse samples. <i>Scientific Data</i> , 2017, 4, 170112.	5.3	195
18	A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 181-187.	2.0	194

#	ARTICLE	IF	CITATIONS
19	Transcription and enhancer profiling in human monocyte subsets. Blood, 2014, 123, e90-e99.	1.4	157
20	Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Current Opinion in Immunology, 2011, 23, 679-684.	5.5	153
21	Bioluminescence imaging of lymphocyte trafficking in vivo. Experimental Hematology, 2001, 29, 1353-1360.	0.4	146
22	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematology, the, 2016, 3, e388-e397.	4.6	128
23	Isolation of CD4+CD25+ Regulatory T Cells for Clinical Trials. Biology of Blood and Marrow Transplantation, 2006, 12, 267-274.	2.0	123
24	The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. Blood, 2014, 123, e68-e78.	1.4	77
25	Mechanisms governing the pioneering and redistribution capabilities of the non-classical pioneer PU.1. Nature Communications, 2020, 11, 402.	12.8	76
26	Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods, 2003, 31, 172-179.	3.8	75
27	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Annals of Hematology, 2015, 94, 2015-2024.	1.8	67
28	Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. Journal of Clinical Immunology, 2002, 22, 131-136.	3.8	62
29	Dominant Th2 Differentiation of Human Regulatory T Cells upon Loss of FOXP3 Expression. Journal of Immunology, 2012, 188, 1275-1282.	0.8	60
30	Epigenetic reprogramming of the <i>RORC</i> locus during in vitro expansion is a distinctive feature of human memory but not na�ve Treg. European Journal of Immunology, 2011, 41, 1491-1498.	2.9	57
31	CD4+CD25+ Regulatory T Cells and Graft-Versus-Host Disease. Seminars in Hematology, 2006, 43, 62-69.	3.4	55
32	Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome. Molecular Imaging, 2004, 3, 1-8.	1.4	54
33	Novel Serial Positive Enrichment Technology Enables Clinical Multiparameter Cell Sorting. PLoS ONE, 2012, 7, e35798.	2.5	54
34	Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood, 2011, 118, 6971-6974.	1.4	52
35	Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell Transplant Centers. Biology of Blood and Marrow Transplantation, 2013, 19, 767-776.	2.0	49
36	CD19+CD21low B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 250-258.	2.0	47

#	ARTICLE	IF	CITATIONS
37	Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: Results of treatment with the COBE Spectra System. Bone Marrow Transplantation, 2013, 48, 439-445.	2.4	42
38	TLR5 stop codon polymorphism is associated with invasive aspergillosis after allogeneic stem cell transplantation. Medical Mycology, 2013, 51, 818-825.	0.7	42
39	Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia, 2016, 30, 562-569.	7.2	42
40	Haploidentical CD3 or $\hat{1}\pm/\hat{1}^2$ T-cell depleted HSCT in advanced stage sickle cell disease. Bone Marrow Transplantation, 2019, 54, 1859-1867.	2.4	39
41	Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects. Oncoimmunology, 2015, 4, e981483.	4.6	38
42	Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2016, 7, 595.	4.8	36
43	Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells. Leukemia, 2020, 34, 895-908.	7.2	34
44	Pharmaceutical and Cellular Strategies in Prophylaxis and Treatment of Graft-Versus-Host Disease. Current Pharmaceutical Design, 2009, 15, 1974-1997.	1.9	33
45	Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells. Clinical Cancer Research, 2005, 11, 4561-4570.	7.0	30
46	Regulatory T-Cell Suppression of CD8+ T-Cell-Mediated Graft-Versus-Host Reaction Requires Their Presence During Priming. Transplantation, 2009, 88, 188-197.	1.0	30
47	Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-<i>versus</i>-host disease. Clinical and Experimental Immunology, 2009, 159, 87-92.	2.6	29
48	Whole-Body UVB Irradiation during Allogeneic Hematopoietic Cell Transplantation Is Safe and Decreases Acute Graft-versus-Host Disease. Journal of Investigative Dermatology, 2012, 132, 179-187.	0.7	29
49	Regulatory T cells for the prevention of graft&€œ<i>versus</i>&€œhost disease: Professionals defeat amateurs. European Journal of Immunology, 2009, 39, 2966-2968.	2.9	27
50	Polyclonal Expansion of Human CD4+CD25+ Regulatory T Cells. Methods in Molecular Biology, 2010, 677, 15-30.	0.9	26
51	Langerhans cells promote early germinal center formation in response to <i>Leishmania</i>&€œderived cutaneous antigens. European Journal of Immunology, 2014, 44, 2955-2967.	2.9	23
52	Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Infection, 2012, 40, 153-161.	4.7	22
53	The lack of memory B cells including T cell independent IgM+&€œIgD+ memory B cells in chronic graft-versus host disease is associated with susceptibility to infection. Transplant International, 2012, 25, 87-96.	1.6	22
54	Regulatory Mechanisms in Graft-versus-Host Responses. Biology of Blood and Marrow Transplantation, 2009, 15, 2-6.	2.0	21

#	ARTICLE	IF	CITATIONS
55	IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. <i>Annals of Hematology</i> , 2020, 99, 847-853.	1.8	21
56	Prolonged Suppression of Butyrate-Producing Bacteria Is Associated With Acute Gastrointestinal Graft-vs-Host Disease and Transplantation-Related Mortality After Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2022, 74, 614-621.	5.8	20
57	Lipopeptide-Polyoxyethylene Conjugates as Mitogens and Adjuvants. <i>Immunobiology</i> , 1994, 190, 53-66.	1.9	18
58	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. <i>Haematologica</i> , 2019, 104, 955-962.	3.5	18
59	Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset. <i>Annals of Hematology</i> , 2017, 96, 299-310.	1.8	17
60	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated <i>versus</i> Tâ€cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	2.5	17
61	The Impact of a Tumor Diagnosis on Patients' Attitudes toward Advance Directives. <i>Oncology</i> , 2014, 87, 246-256.	1.9	16
62	Physiologic TLR9-CpG-DNA Interaction Is Essential for the Homeostasis of the Intestinal Immune System. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 136-143.	1.9	15
63	Isolation of intact genomic DNA from FOXP3-sorted human regulatory T cells for epigenetic analyses. <i>European Journal of Immunology</i> , 2010, 40, 1510-1512.	2.9	11
64	Discovery of widespread transcription initiation at microsatellites predictable by sequence-based deep neural network. <i>Nature Communications</i> , 2021, 12, 3297.	12.8	11
65	Driving allotolerance: CAR-expressing Tregs for tolerance induction in organ and stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2016, 126, 1248-1250.	8.2	11
66	Treosulfan conditioning for allogeneic transplantation in multiple myeloma â€ improved overall survival in first line haematopoietic stem cell transplantation â€ a large retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 189, e213-e217.	2.5	10
67	A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001). <i>Frontiers in Medicine</i> , 2020, 7, 634260.	2.6	10
68	Abatacept as salvage therapy in chronic graft-versus-host diseaseâ€a retrospective analysis. <i>Annals of Hematology</i> , 2021, 100, 779-787.	1.8	10
69	Basophils inhibit proliferation of <sc>CD</sc>4⁺<sc>T</sc> cells in autologous and allogeneic mixed lymphocyte reactions and limit disease activity in a murine model of graft versus host disease. <i>Immunology</i> , 2015, 145, 202-212.	4.4	7
70	Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis. <i>Annals of Hematology</i> , 2020, 99, 2181-2190.	1.8	7
71	Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation â€ A single center retrospective efficacy analysis. <i>Vaccine</i> , 2021, 39, 4742-4750.	3.8	7
72	Graft-Versus-Host Disease Impairs Early B Lymphopoiesis in the Bone Marrow. <i>Blood</i> , 2011, 118, 2976-2976.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Immunomodulation after allogeneic bone marrow transplantation by CD4+CD25+ regulatory T cells. <i>Microbes and Infection</i> , 2005, 7, 1066-1072.	1.9	6
74	Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. <i>Radiotherapy and Oncology</i> , 2015, 116, 287-293.	0.6	6
75	GPR Expression in Intestinal Biopsies From SCT Patients Is Upregulated in GvHD and Is Suppressed by Broad-Spectrum Antibiotics. <i>Frontiers in Immunology</i> , 2021, 12, 753287.	4.8	6
76	CD4+ CD25+ regulatory T cells approach the clinic. <i>Cytotherapy</i> , 2008, 10, 655-656.	0.7	5
77	Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease—single center experience. <i>Annals of Hematology</i> , 2019, 98, 2399-2405.	1.8	5
78	Low Intestinal IL22 Associates With Increased Transplant-Related Mortality After Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2022, 13, 857400.	4.8	5
79	Evaluation of the Cost of Survivorship Care After Allogeneic Hematopoietic Stem Cell Transplantation—An Analysis of 2 German Transplantation Centers. <i>Frontiers in Public Health</i> , 2020, 8, 572470.	2.7	4
80	Loss of FOXP3 Expression and Emergence of Cytokine-Producing Cells after In Vitro Expansion of Human CD4+CD25+CD127 - Regulatory T Cells. <i>Blood</i> , 2007, 110, 63-63.	1.4	4
81	Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission. <i>Blood</i> , 2021, 138, 1783-1783.	1.4	4
82	A new approach for eradication of residual lymphoma cells by host nonreactive anti-“third-party central memory CD8 T cells. <i>Blood</i> , 2013, 121, 3033-3040.	1.4	3
83	Delayed Onset of T Cell-Mediated Xenogeneic Disease in Rag2 ^{Δγ} /Δγ ^{Δγ} mice after Co- Transplantation of in Vitro Expanded Human CD4+CD25 ^{high} CD45RA ⁺ Regulatory T Cells. <i>Blood</i> , 2008, 112, 4609-4609.	1.4	3
84	Stem Cell Transplantation in Advanced Stage Sickle Cell Disease with Haploidentical T-Cell Depleted PBSC Yields Comparable Outcomes to Matched Sibling Donor Bone Marrow: Results of a Pilot Study. <i>Blood</i> , 2018, 132, 3455-3455.	1.4	2
85	Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome. <i>Molecular Imaging</i> , 2004, 3, 153535002004031.	1.4	1
86	Only MHC-Identical Donor CD4+CD25+ Regulatory T Cells Convey Full Protection from Lethal Graft-Versus-Host Disease. <i>Blood</i> , 2008, 112, 3516-3516.	1.4	1
87	Efficient Treatment of Murine Acute Graft-Versus-Host Disease with In Vitro Expanded CD4+CD25+ Regulatory T Cells. <i>Blood</i> , 2011, 118, 2987-2987.	1.4	1
88	Functionally Defined T Cell Subsets in Transplantation Biology and Therapy: Regulatory T Cells and Th2 Cells. <i>Cancer Treatment and Research</i> , 2009, 144, 155-186.	0.5	1
89	Assessment of Calcineurin Inhibitor-Associated Neurotoxicity in Patients with Sickle Cell Disease Receiving a Matched Sibling Donor or T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2088-2088.	1.4	1
90	Immunoregulation in human bone marrow transplantation?. <i>Blood</i> , 2004, 104, 1920-1920.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Natural CD4+CD25+FOXP3+ regulatory T cells in graft-versus-host disease. , 2013, , 245-270.		0
92	Thymus-Derived CD4+CD25+ FOXP3+ Regulatory T Cells in GVHD. , 2019, , 211-229.		0
93	International Regensburg Center for Interventional Immunology (RCI) symposium on "Synthetic immunology and environment-adapted redirection of T cells" 17-18 July, 2019, Regensburg, Germany. Cancer Immunology, Immunotherapy, 2020, 69, 677-682.	4.2	0
94	Isolation of Human CD4+CD25+ T Cells with Regulatory Capacity for Clinical Trials.. Blood, 2004, 104, 2851-2851.	1.4	0
95	Inhibitory Effects of Lactic Acid on Human Antigen-Specific CD8+ T-Cells.. Blood, 2004, 104, 3844-3844.	1.4	0
96	Low-Dose Cyclosporin A Does Not Abrogate the Suppressive Function of In Vitro Expanded Human CD4+CD25+ Regulatory T Cells.. Blood, 2006, 108, 5170-5170.	1.4	0
97	Only Naive CD45RA+CD4+CD25 ^{high} T Cells from Human Peripheral Blood Give Rise to Homogeneous Regulatory T Cell Lines.. Blood, 2006, 108, 3163-3163.	1.4	0
98	Increased Susceptibility to Fungal Infection in Recipients with GVHD Is Not Due to Impaired Pathogen Clearance and Can Be Prevented by Co-Transfer of Donor CD4+CD25+ Regulatory T Cells. Blood, 2011, 118, 822-822.	1.4	0
99	Regulatory T Cells Preserve Anti-Viral Immunity While Preventing Lethal Graft-Versus-Host Disease. Blood, 2013, 122, 5432-5432.	1.4	0
100	Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA. Blood, 2015, 126, 1581-1581.	1.4	0
101	Profiling T Cell Receptor Repertoires in Phase I/II Clinical Trials of Donor Treg Infusion for the Treatment of Chronic Graft-Versus-Host Disease. Blood, 2018, 132, 4563-4563.	1.4	0